Conference Call Participants
Arjun Seth
Avery LaChance
Rohit Aggarwal
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Andy Chen – Wolfe Research, LLC
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Tazeen Ahmad – BofA Securities, Research Division
David Nierengarten – Wedbush Securities Inc., Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Shuting Cai – TD Cowen, Research Division
Xian Deng – UBS Investment Bank, Research Division
Danielle Brill Bongero – Truist Securities, Inc., Research Division
Sophia Graeff Buhl Nielsen – JPMorgan Chase & Co, Research Division
Jiayi Yuan – RBC Capital Markets, Research Division
Akash Tewari – Jefferies LLC, Research Division
Rajan Sharma – Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Please welcome Beth DelGiacco.
Beth DelGiacco
Hi, and welcome to our Boston Innovation Hub. It’s looking very transformed today. And welcome to our second R&D Spotlight event. Today, we’re going to focus on autoimmune myositis and the opportunity for VYVGART to have a meaningful impact on patients’ lives. We have a full house today. We have many investors and analysts. We also have our argenx colleagues here. And during that mix and mingle, we encourage you to get to know each other. We also have a lot of people joining on the webcast. So a big welcome to them as well.
Autoimmune myositis. We’ve actually transitioned from calling this disease or what is really a group of different diseases away from idiopathic inflammatory myopathies because idiopathic means of unknown origin. And the reality is, today, we know what drives myositis, which is our immune system. And so you’re going to
